Novo Nordisk enters the US market with the oral weight loss pill Wegovy

The U.S. Food and Drug Administration (FDA) has approved the weight loss pill developed by Novo Nordisk, giving the Danish company a significant advantage in the American obesity treatment market. The oral medication, which contains 25 mg of semaglutide – the same active ingredient in Wegovy and Ozempic – will be marketed under the Wegovy brand and is intended for the chronic management of weight in adults with obesity or overweight, marking a strategic step for Novo in direct competition with rival Eli Lilly.